| November 26, 2014 | ISSUE NUMBER 379 VOL 4 |
|
Special Report
How Gilead “Blew Out the Lights” with Sovaldi
A report by ISI’s Mark Schoenenbaum shows that Gilead’s Sovaldi literally "blew out the lights" in U.S. specialty drug sales during its first full year on the market. It will generate somewhere between $10 and $11 billion dollars in sales for 2014. In light of this spectacular success, Tom Norton wonders how Sovaldi’s first year compares against drugs in the broader chronic categories ...Read more
E-Book: Celebrating 50 Years of DIA
This commemorative e-book includes special articles, as well as DIA session highlights and news that pharmaceutical and clinical trial professionals will find important and informative.  Download Today
Drug Development and Approval
Breakthrough Therapy Program Exceeds FDA’s Expectations
The two-year-old initiative to accelerate the development and approval of highly effective drugs and biologics has enabled a number of important new medicines to reach patients sooner, according to Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER) ...Read more
Access to Medicines
GSK and Novo Nordisk Lead on Access List
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries. For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores ...Read more
Global
Read the Pharm Exec Global Digest ‘Toward 2015’ Special
In this month’s issue: Europe and Transparency in 2015; Cloud Technology: a Five-Year Outlook; Brazil’s Revised Growth Forecast; Warehousing and the Future of the HCV Treatment Market; and more
...Read more
|
|
|
|
 //NeoStem (New York, NY) announced that Dr. Robert Preti, its Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy, has been named Vice Chairman of the Alliance for Regenerative Medicine (ARM).//Lion Biotechnologies (Los Angeles, CA) announced that its Chief Executive Officer Manish Singh, Ph.D., is resigning for personal reasons, effective December 31, 2014.//James Gower is retiring from the Board of Directors and from his positions as Chairman and Chief Executive Officer of Rigel Pharmaceuticals (South San Francisco, CA). Raul Rodriguez, who has served as the company's President and Chief Operating Officer, will assume the position of CEO and join the Board of Directors. Gary Lyons will become Chairman.// |
|
|
|
|
|
 |
|
|
 |
Which of the following is your most important upcoming initiative?
|
|
|
|
